THE TRUTH ABOUT: 12 - Caught on Camera

3 High-Quality Stocks to Pick Up for the Second-Half

The bear market provides an opportunity for investors to buy shares of high-quality companies at attractive valuations. Below are 3 such stocks that investors should consider buying during this market correction: Elevance Health (ELVH), Pfizer (PFE), and Builders FirstSource (BLDR).

StockNews.com · Jul 26, 2022

2 Stocks Hedge Funds Have Been Buying up in 2022

Amid the bear market, hedge funds have been buying shares of Merck & Co. (MRK) and Pfizer (PFE). This, along with the strong fundamentals and growth prospects of these stocks, makes them good additions to your watchlist. Let’s discuss.

StockNews.com · Jul 25, 2022

Is Buying Pfizer Stock Right Now a Mistake?

Popular pharmaceutical company Pfizer (PFE) has entered into an agreement with the U.S. government to provide more COVID-19 vaccines. However, the stock is down more than 13% this year. Hence, will it be wise to invest in the stock now? Read on to find out….

StockNews.com · Jul 21, 2022

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19.  Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga · Jun 30, 2022

US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization.  The doses are planned to be delivered…

Benzinga · Jun 30, 2022

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant.  Pfizer holds a 25%…

Benzinga · Jun 28, 2022

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Jun 22, 2022

Pfizer Strikes Deal With French Vaccine Maker -- Buy Or Sell?

Pharmaceutical company Pfizer (PFE) reported impressive first-quarter financials and is well-positioned to benefit from the equity subscription agreement with French vaccine maker Valneva. However, given the growing economic uncertainty, would it be worth adding the stock to your portfolio? Read more to find out.

StockNews.com · Jun 22, 2022

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age.  Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA…

Benzinga · Jun 17, 2022

Pfizer Halts Enrollment In Paxlovid COVID-19 Trial In Standard-Risk Population

Pfizer Inc (NYSE:PFE) shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid (nirmatrelvir and ritonavir tablets) in patients at standard risk for developing severe COVID-19.  In previously reported interim analyses, the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met. Non-significant 70% relative…

Benzinga · Jun 15, 2022